Skin graft studies
. | . | . | . | . | . | . | . | . | Skin grafts . | . | . | . | . | . | . | . | . | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | Pretransplantation donor platelet transfusions . | . | . | . | . | . | . | . | . | Third-party donors . | . | Posttransplantation donor platelet transfusions . | . | . | . | . | . | |||||||||||||
| Recipient dog no. . | Initial donor's F-LR/C-LR platelets . | . | Initial donor, standard . | . | Second donor, standard . | . | Third donor, standard . | . | Initial donor . | Second donor . | Third donor . | Initial donor, standard . | . | Second donor, standard . | . | Third donor, standard . | . | |||||||||||||
| E652 | A | – | A | – | A | – | A | – | A | ND | R | A | + | A | + | R | + | |||||||||||||
| E281 | A | – | A | – | A | – | A | – | A | ND | R | A | + | A | + | A | + | |||||||||||||
| E238 | A | – | A | – | R | – | R | – | A | R | ND | A | – | ND | + | R | + | |||||||||||||
| E181 | A | – | A | – | A | – | A | – | R | A | ND | A | – | A | + | A | + | |||||||||||||
| E368 | A | – | ND | ND | ND | ND | ND | ND | R | ND | ND | R | + | ND | ND | ND | ND | |||||||||||||
| E308 | A | ND | A | + | A | – | R | – | ND | R | ND | A | + | A | + | A | + | |||||||||||||
| E106 | A | ND | A | – | R | – | A | – | R | ND | R | A | + | ND | ND | R | + | |||||||||||||
. | . | . | . | . | . | . | . | . | Skin grafts . | . | . | . | . | . | . | . | . | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | Pretransplantation donor platelet transfusions . | . | . | . | . | . | . | . | . | Third-party donors . | . | Posttransplantation donor platelet transfusions . | . | . | . | . | . | |||||||||||||
| Recipient dog no. . | Initial donor's F-LR/C-LR platelets . | . | Initial donor, standard . | . | Second donor, standard . | . | Third donor, standard . | . | Initial donor . | Second donor . | Third donor . | Initial donor, standard . | . | Second donor, standard . | . | Third donor, standard . | . | |||||||||||||
| E652 | A | – | A | – | A | – | A | – | A | ND | R | A | + | A | + | R | + | |||||||||||||
| E281 | A | – | A | – | A | – | A | – | A | ND | R | A | + | A | + | A | + | |||||||||||||
| E238 | A | – | A | – | R | – | R | – | A | R | ND | A | – | ND | + | R | + | |||||||||||||
| E181 | A | – | A | – | A | – | A | – | R | A | ND | A | – | A | + | A | + | |||||||||||||
| E368 | A | – | ND | ND | ND | ND | ND | ND | R | ND | ND | R | + | ND | ND | ND | ND | |||||||||||||
| E308 | A | ND | A | + | A | – | R | – | ND | R | ND | A | + | A | + | A | + | |||||||||||||
| E106 | A | ND | A | – | R | – | A | – | R | ND | R | A | + | ND | ND | R | + | |||||||||||||
A indicates accepted; ND, not done; and R, rejected.
For platelet transfusions, the recipient accepted 8 weeks of transfusions either from their initial donor (first donor) or third-party donors (second or third donor in order received). For the skin grafts, the recipient accepted a graft from either their initial or one of their third-party donors (second or third donor). For platelet transfusions, the recipient rejected either platelets from their initial donor or third-party donors (second or third donor). For the skin grafts, the recipient rejected a graft from either their initial or one of their third-party donors (second or third donor). The results of lymphocytotoxic antibody cross-match tests using recipient serum and donor lymphocytes is given as positive (+) or negative (–) beside the results of the corresponding platelet transfusion. The serum used for testing was drawn during the week the platelet survival studies were done.